These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...

AB-1005 has received U.S. FDA Fast Track and UK Medicines and Healthcare products Regulatory Agency ... rigorous assessment and prioritization, Bayer Pharmaceuticals is now fully focused on ...

At the same time, the value of our pipeline is growing by accelerating breakthrough innovations," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...

Bayer today announced topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic ...

Bayer is just the latest in a string of big pharma companies to invest in firms ... Bayer's protein engineering know-how for use in CRISPR products as well as Bayer's extensive expertise and ...

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none,” the company's products and ...

However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...